AHA Issues First Deprescribing Guidance for Heart Patients on Too Many Drugs
A new American Heart Association statement tackles polypharmacy in cardiovascular patients, offering the first lifespan-spanning deprescribing framework.
Summary
Many patients with heart disease take so many medications that the drugs themselves become a health hazard. Despite this being a recognized problem for decades, clinicians have lacked clear guidance on when and how to safely reduce medication burdens. The American Heart Association has now issued a formal scientific statement addressing this gap. It covers the risks of polypharmacy across all ages — from children to older adults — and outlines practical strategies for deprescribing, meaning the deliberate, supervised reduction or stopping of medications. Key strategies include recognizing clinical warning signs, using validated assessment tools, involving patients in shared decision-making, and coordinating across the entire care team. Both heart and non-heart medications are addressed, since both contribute to the problem.
Detailed Summary
Patients with cardiovascular disease are among the heaviest users of prescription medications, often taking drugs for blood pressure, cholesterol, heart rhythm, diabetes, and other comorbidities simultaneously. This cumulative burden — known as polypharmacy — is common across all age groups and is associated with adverse drug reactions, drug-drug interactions, reduced adherence, hospitalizations, and worse outcomes overall. Yet until now, the cardiology community has had little formal guidance on how to address it.
This scientific statement from the American Heart Association represents the first comprehensive framework specifically targeting deprescribing in cardiovascular patients. Deprescribing refers to the systematic, evidence-based process of reducing, tapering, or stopping medications that are no longer appropriate, beneficial, or safe for a given patient. Importantly, the statement applies to both cardiovascular and non-cardiovascular drugs, since all medications in a patient's regimen contribute to polypharmacy risk.
The statement provides tailored strategies across the lifespan, recognizing that pediatric, adult, and older adult populations each face unique challenges. For older adults in particular, physiological changes in drug metabolism, increased sensitivity to side effects, and higher rates of multimorbidity amplify polypharmacy risks. The guidance recommends monitoring for clinical cues and triggers that signal a medication may be causing harm or is no longer needed, employing validated deprescribing tools, and engaging patients and caregivers through shared decision-making.
The statement also addresses systemic barriers to deprescribing — including clinician inertia, fragmented care, and patient resistance — and calls on all members of the healthcare team, including pharmacists, nurses, and primary care providers, to play active roles.
For clinicians managing complex cardiovascular patients, this document provides long-overdue practical scaffolding. Limitations include the fact that evidence gaps in deprescribing trials remain, and this is a consensus statement rather than a meta-analysis of randomized data.
Key Findings
- Polypharmacy in cardiovascular patients occurs at all ages and is linked to adverse drug events and poor outcomes.
- Deprescribing both cardiac and non-cardiac medications can improve patient outcomes and reduce harm.
- Validated deprescribing tools and shared decision-making are central to the AHA's recommended approach.
- Unique considerations exist for pediatric, adult, and older adult cardiovascular patients when reducing medications.
- Systemic barriers including clinician inertia and fragmented care must be addressed to enable effective deprescribing.
Methodology
This is a scientific statement — a formal consensus document from the American Heart Association's Clinical Pharmacology Committee and multiple AHA councils. It synthesizes existing literature on polypharmacy and deprescribing rather than presenting original trial data. The statement is structured to provide clinical guidance across the full patient lifespan.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. The statement is a consensus document rather than a systematic review or meta-analysis, so its recommendations reflect expert opinion informed by available evidence rather than pooled trial data. Specific drug-by-drug deprescribing protocols and the strength of underlying evidence cannot be assessed without the full text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: